An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer

Trial Profile

An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs AZD 9496 (Primary) ; Fulvestrant
  • Indications Breast cancer
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 30 Nov 2018 to 7 Dec 2018.
    • 13 Nov 2017 Planned primary completion date changed from 30 Nov 2018 to 7 Dec 2018.
    • 11 Oct 2017 Planned End Date changed from 5 Dec 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top